These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

200 related articles for article (PubMed ID: 12470210)

  • 21. A work in progress: the clinical development of histone deacetylase inhibitors.
    Marsoni S; Damia G; Camboni G
    Epigenetics; 2008; 3(3):164-71. PubMed ID: 18487953
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Histone lysine demethylases as targets for anticancer therapy.
    Højfeldt JW; Agger K; Helin K
    Nat Rev Drug Discov; 2013 Dec; 12(12):917-30. PubMed ID: 24232376
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Effect of the histone deacetylase inhibitor trichostatin a in human peripheral blood lymphocytes as a function of donor age.
    Sourlingas TG; Kypreou KP; Topakas GN; Karchilaki IN; Stavropoulos-Giokas C; Sekeri-Pataryas KE
    Ann N Y Acad Sci; 2007 Nov; 1119():64-71. PubMed ID: 18056955
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Histone deacetylase inhibitors in hematological malignancies and solid tumors.
    Chun P
    Arch Pharm Res; 2015 Jun; 38(6):933-49. PubMed ID: 25653088
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Selective Histone Deacetylase Inhibitors with Anticancer Activity.
    Ma N; Luo Y; Wang Y; Liao C; Ye WC; Jiang S
    Curr Top Med Chem; 2016; 16(4):415-26. PubMed ID: 26268343
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Histone deacetylase inhibitors as new cancer drugs.
    Marks PA; Richon VM; Breslow R; Rifkind RA
    Curr Opin Oncol; 2001 Nov; 13(6):477-83. PubMed ID: 11673688
    [TBL] [Abstract][Full Text] [Related]  

  • 27. From discovery to the coming generation of histone deacetylase inhibitors.
    Yoshida M; Matsuyama A; Komatsu Y; Nishino N
    Curr Med Chem; 2003 Nov; 10(22):2351-8. PubMed ID: 14529478
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Multi-targeted histone deacetylase inhibitors in cancer therapy.
    Ai T; Cui H; Chen L
    Curr Med Chem; 2012; 19(4):475-87. PubMed ID: 22204328
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Acetylation of proteins as novel target for antitumor therapy: review article.
    Di Gennaro E; Bruzzese F; Caraglia M; Abruzzese A; Budillon A
    Amino Acids; 2004 Jul; 26(4):435-41. PubMed ID: 15290351
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Histone deacetylase inhibitors in clinical studies as templates for new anticancer agents.
    Mottamal M; Zheng S; Huang TL; Wang G
    Molecules; 2015 Mar; 20(3):3898-941. PubMed ID: 25738536
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Histone deacetylase inhibitors in cancer therapy.
    Fouladi M
    Cancer Invest; 2006; 24(5):521-7. PubMed ID: 16939962
    [No Abstract]   [Full Text] [Related]  

  • 32. Short-chain fatty acid inhibitors of histone deacetylases: promising anticancer therapeutics?
    Chen JS; Faller DV; Spanjaard RA
    Curr Cancer Drug Targets; 2003 Jun; 3(3):219-36. PubMed ID: 12769690
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Belinostat: a new broad acting antineoplastic histone deacetylase inhibitor.
    Gimsing P
    Expert Opin Investig Drugs; 2009 Apr; 18(4):501-8. PubMed ID: 19335278
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Molecular basis of the anti-cancer effects of histone deacetylase inhibitors.
    Epping MT; Bernards R
    Int J Biochem Cell Biol; 2009 Jan; 41(1):16-20. PubMed ID: 18765293
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Histone deacetylase inhibitors: mechanisms and clinical significance in cancer: HDAC inhibitor-induced apoptosis.
    Shankar S; Srivastava RK
    Adv Exp Med Biol; 2008; 615():261-98. PubMed ID: 18437899
    [TBL] [Abstract][Full Text] [Related]  

  • 36. [Assay for inhibitory activity of histone deacetylase].
    Yoshida M
    Gan To Kagaku Ryoho; 2004 Apr; 31(4):507-11. PubMed ID: 15114691
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Inhibitors of histone deacetylase as new anticancer agents.
    Jung M
    Curr Med Chem; 2001 Oct; 8(12):1505-11. PubMed ID: 11562279
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Histone deacetylase inhibitors sit at crossroads of diet, aging, cancer.
    Hede K
    J Natl Cancer Inst; 2006 Mar; 98(6):377-9. PubMed ID: 16537828
    [No Abstract]   [Full Text] [Related]  

  • 39. Histone deacetylase inhibitors and demethylating agents: clinical development of histone deacetylase inhibitors for cancer therapy.
    Piekarz RL; Sackett DL; Bates SE
    Cancer J; 2007; 13(1):30-9. PubMed ID: 17464244
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Selective inhibitors of zinc-dependent histone deacetylases. Therapeutic targets relevant to cancer.
    Kollar J; Frecer V
    Curr Pharm Des; 2015; 21(11):1472-502. PubMed ID: 25382430
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.